Skip to content

Postherpetic and postsurgical neuropathic pain

TL;DR — PHN follows varicella-zoster ganglion/nerve injury; postsurgical neuropathic pain follows procedural nerve injury. Across 130 zoster studies, PHN affected 5% to >30% and >30% of PHN persisted beyond one year in some cohorts (Kawai 2014, PMID 24916088). Among people with persistent postsurgical pain, probable/definite neuropathic proportions were 68% after breast surgery, 66% thoracic, 31% hernia and 6% arthroplasty (Haroutiunian 2013, PMID 23273105). Vaccination prevents zoster/PHN; no perioperative drug reliably prevents chronic postsurgical pain.

Definitions

PHN commonly means dermatomal pain ≥90 days after rash, but 30-, 90- and 120-day thresholds impede comparison (Saguil 2017, PMID 29431387). Persistent postsurgical pain is pain beyond expected healing, usually ≥3 months, with other causes excluded (Rosenberger 2022, PMID 35496645).

Biology

PHN combines ganglionitis, axonal loss and surviving-fiber hyperexcitability; surgical injury combines transection, traction, compression, ischemia and neuroma (Watson 2011, PMID 21916395).

These syndromes share nerve injury but differ in timing and prevention. Zoster produces inflammatory injury within a dermatome; surgery creates a mechanically defined exposure whose nerve involvement varies by approach. Ongoing nociceptive input from scar, joint, pleura or cancer recurrence may coexist with neuropathic pain, so a single label should not replace localization.

Mechanism PHN Postsurgical neuropathic pain
Initial insult Viral reactivation and ganglion/nerve inflammation Transection, traction, compression, ischemia
Persistent generator Deafferentation plus surviving-fiber hyperexcitability Neuroma, entrapment, scar and central amplification
Mixed-pain source Skin inflammation during acute zoster Musculoskeletal, visceral, scar or recurrent disease
Prevention target Zoster prevention and early acute care Procedure-specific nerve preservation and acute recovery

PHN frequency

Zoster incidence is commonly 3–5/1,000 person-years; PHN risk spans 5% to >30% depending on age and definition (Kawai 2014, PMID 24916088).

Vaccination

In 38,546 adults ≥60, vaccine versus placebo produced 315 versus 642 zoster cases and 27 versus 80 PHN cases over median 3.12 years (Oxman 2005, PMID 15930418). Post-licensure synthesis confirms product- and immune-status-dependent effectiveness (Mbinta 2022, PMID 36098300).

A 2024 meta-analysis of nine randomized trials of recombinant vaccine estimated 140 fewer zoster cases per 1,000 in high-risk populations but 28 fewer per 1,000 in healthy populations; it found no statistically significant PHN difference and more non-serious adverse events, without a serious-adverse-event difference (Bengolea 2024, PMID 39399936). The PHN result should not be read as evidence of no preventive pathway: PHN is downstream of zoster, events are fewer, and trials may be underpowered for that complication.

PHN treatment

Gabapentinoids, TCAs and topical agents are used; capsaicin has stronger randomized evidence than lidocaine, whose evidence is very low quality (Derry 2017, PMID 28085183); (Derry 2014, PMID 25058164).

Postsurgical distribution

The neuropathic proportion among persistent pain varies with nerve-injury exposure: breast 68%, thoracic 66%, hernia 31%, arthroplasty 6% (Haroutiunian 2013, PMID 23273105). These are conditional proportions, not surgical incidence.

Risk and prevention

Severe acute pain predicts persistence, but stronger acute analgesia has not been shown reliably to prevent chronic neuropathic pain (Blichfeldt-Eckhardt 2018, PMID 29510808). Nerve-sparing technique is procedure-specific.

Among 19,813 breast-surgery patients in 30 observational studies, persistent-pain odds rose with each 10-year decrement in age (OR 1.36, 95% CI 1.24–1.48), radiotherapy (OR 1.35, 1.16–1.57), axillary dissection (OR 2.41, 1.73–3.35) and each 1-cm increase in acute pain on a 10-cm scale (OR 1.16, 1.03–1.30) (Wang 2016, PMID 27402075). Associations identify risk strata, not proven prevention targets.

A 187-study synthesis covering 297,612 breast-surgery patients estimated pooled persistent pain at 35% (95% CI 32–39), with pooled intensity 3.9/10 (3.6–4.2); patient-reported moderate-to-severe pain at any location was 27% (10–43) after adjustment (Wang 2020, PMID 32611524). Definitions and ascertainment drove large variation: clinician-assessed prevalence was 23% versus 36% by patient report.

Perioperative evidence is sharper for acute than chronic benefit. In 73 breast-surgery trials/5,512 patients, paravertebral and pectoralis blocks and glucocorticoids reduced acute pain or opioid use, but chronic-pain data were insufficient (Lepot 2021, PMID 32816362). This is the central prevention controversy: acute pain is prognostic, yet reducing acute pain has not consistently reduced chronic neuropathic pain.

Procedure modification also needs randomized confirmation. In 90 thoracotomy patients, a nerve-sparing technique did not change worst acute pain (difference 0.12/10; 99% CI −0.7 to 0.9) or six-month chronic pain (37.8% versus 40%; difference 4.9%, 99% CI −22.8 to 30.7) (Jiwnani 2019, PMID 30195601).

PHN risk controversy

A 53-cohort meta-analysis associated more extensive skin lesions, treatment starting ≥3 days after onset and comorbidity with PHN, but found no significant association for female sex (OR 1.13, 95% CI 0.99–1.29) or glucocorticoid use (OR 0.61, 0.22–1.70) (Ding 2024, PMID 39029866). Cohort associations cannot settle whether earlier antivirals prevent PHN because treatment timing is confounded by severity and access; randomized prevention endpoints remain more informative.

Question Evidence supporting action Counterweight
Vaccinate Fewer zoster cases and downstream opportunities for PHN Absolute benefit depends on baseline risk; reactogenicity
Treat zoster early Later presentation associates with PHN Observational timing confounding
Intensify acute analgesia Acute pain predicts persistence Chronic-prevention trials remain inconclusive
Preserve nerves Strong mechanistic rationale Procedure-specific RCTs can be neutral
Use perioperative blocks Acute pain/opioid benefit Chronic neuropathic prevention unproved

Focal workup

Map pain to named nerves/scar, document gain/loss and consider structural imaging or a carefully interpreted block. Anesthetic spread and expectation limit block specificity (Lin 2019, PMID 31151330).

Comparison

Feature PHN Postsurgical pain
Trigger VZV reactivation Procedure-related injury
Distribution Dermatome Nerve/scar territory
Prevention Vaccination Technique/risk reduction
Topical role Common Common when localized
Red flag Ophthalmic/disseminated zoster Infection, hematoma, new deficit

Evidence interpretation map

The table makes the evidence role and inferential boundary explicit; it is not a replacement for the full reports.

PMID Year Evidence role What it cannot establish alone
15930418 2005 Large randomized live-zoster-vaccine trial Current recombinant-vaccine effectiveness
39399936 2024 Recombinant-vaccine RCT meta-analysis Individual net benefit
27402075 2016 Breast-surgery prognostic meta-analysis Causal prevention effects
32611524 2020 Prevalence meta-analysis Neuropathic fraction in every procedure
30195601 2019 Thoracotomy technique RCT Effects in other surgical approaches

Minimum reporting controls

Domain Required report
Case definition Possible, probable or definite neuropathic pain
Etiology Lesion/disease and diagnostic evidence
Distribution Focal, length-dependent, dermatomal, at-level or below-level
Baseline phenotype Negative and positive sensory signs
Comparator Placebo/sham, active care or natural history
Exposure Dose, duration, adherence and co-interventions
Benefit Mean change plus ≥30% and ≥50% responders where applicable
Function Sleep, mobility, participation and patient global change
Harm Adverse events, withdrawals and serious events
Durability Follow-up after treatment and attrition
Subgroups Prespecified interaction test, not within-group significance
Missingness Denominator and imputation method

Reporting cautions

  • Do not infer lesion presence from a symptom descriptor.
  • Do not convert a group-average association into an individual diagnostic rule.
  • Do not treat statistical significance as clinically important benefit.
  • Do not compare NNTs without checking outcome threshold, duration and population.
  • Do not interpret an inactive or completed registry record as proof of efficacy.
  • Do not merge painful and painless neuropathy outcomes.
  • Do not omit adverse-event withdrawals from responder interpretation.
  • Do not call a post hoc subgroup predictive without an interaction test.
  • Do not generalize a focal peripheral result to central neuropathic pain.
  • State when evidence is short-term, indirect or restricted to a selected cohort.

Open questions

  • OQ-1: Which acute-zoster intervention adds prevention beyond vaccination?
  • OQ-2: Can nerve mapping reduce absolute surgical incidence?
  • OQ-3: Which early sensory trajectory predicts persistence?
  • OQ-4: Do block responders gain durable focal-treatment benefit?

References

  1. Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4:e004833. PMID 24916088
  2. Haroutiunian S, Nikolajsen L, Finnerup NB, et al.. The neuropathic component in persistent postsurgical pain: a systematic literature review. Pain. 2013;154:95-102. PMID 23273105
  3. Saguil A, Kane S, Mercado M, et al.. Herpes Zoster and Postherpetic Neuralgia: Prevention and Management. Am Fam Physician. 2017;96:656-663. PMID 29431387
  4. Rosenberger DC, Pogatzki-Zahn EM. Chronic post-surgical pain - update on incidence, risk factors and preventive treatment options. BJA Educ. 2022;22:190-196. PMID 35496645
  5. Watson P. Postherpetic neuralgia. Am Fam Physician. 2011;84:690-2. PMID 21916395
  6. Oxman MN, Levin MJ, Johnson GR, et al.. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352:2271-84. PMID 15930418
  7. Mbinta JF, Nguyen BP, Awuni PMA, et al.. Post-licensure zoster vaccine effectiveness against herpes zoster and postherpetic neuralgia in older adults: a systematic review and meta-analysis. Lancet Healthy Longev. 2022;3:e263-e275. PMID 36098300
  8. Derry S, Rice AS, Cole P, et al.. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017;1:CD007393. PMID 28085183
  9. Derry S, Wiffen PJ, Moore RA, et al.. Topical lidocaine for neuropathic pain in adults. Cochrane Database Syst Rev. 2014;2014:CD010958. PMID 25058164
  10. Blichfeldt-Eckhardt MR. From acute to chronic postsurgical pain: the significance of the acute pain response. Dan Med J. 2018;65. PMID 29510808
  11. Lin CS, Lin YC, Lao HC, et al.. Interventional Treatments for Postherpetic Neuralgia: A Systematic Review. Pain Physician. 2019;22:209-228. PMID 31151330
  12. Johnson RW, Rice AS. Clinical practice. Postherpetic neuralgia. N Engl J Med. 2014;371:1526-33. PMID 25317872
  13. Sampathkumar P, Drage LA, Martin DP. Herpes zoster (shingles) and postherpetic neuralgia. Mayo Clin Proc. 2009;84:274-80. PMID 19252116
  14. Snedecor SJ, Sudharshan L, Cappelleri JC, et al.. Systematic review and meta-analysis of pharmacological therapies for pain associated with postherpetic neuralgia and less common neuropathic conditions. Int J Clin Pract. 2014;68:900-18. PMID 24698515
  15. Wiffen PJ, Derry S, Bell RF, et al.. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017;6:CD007938. PMID 28597471
  16. Derry S, Bell RF, Straube S, et al.. Pregabalin for neuropathic pain in adults. Cochrane Database Syst Rev. 2019;1:CD007076. PMID 30673120
  17. Finnerup NB, Attal N, Haroutounian S, et al.. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14:162-73. PMID 25575710
  18. Jiang X, Li Y, Chen N, et al.. Corticosteroids for preventing postherpetic neuralgia. Cochrane Database Syst Rev. 2023;12:CD005582. PMID 38050854
  19. Belizan M, Augustovski F, Bardach A, et al.. Patient Experience of Herpes Zoster Disease in Argentina: Validation of a Health-Related Quality of Life Conceptual Model. Value Health Reg Issues. 2024;44:101044. PMID 39232368
  20. Wareham DW. Postherpetic neuralgia. BMJ Clin Evid. 2007;2007. PMID 19454113
  21. Watson PN. Postherpetic neuralgia. BMJ Clin Evid. 2010;2010. PMID 21418680
  22. Tang J, Zhang Y, Liu C, et al.. Therapeutic Strategies for Postherpetic Neuralgia: Mechanisms, Treatments, and Perspectives. Curr Pain Headache Rep. 2023;27:307-319. PMID 37493871
  23. Huerta MÁ, Garcia MM, García-Parra B, et al.. Investigational Drugs for the Treatment of Postherpetic Neuralgia: Systematic Review of Randomized Controlled Trials. Int J Mol Sci. 2023;24. PMID 37629168
  24. Boogaard S, Heymans MW, de Vet HC, et al.. Predictors of Persistent Neuropathic Pain--A Systematic Review. Pain Physician. 2015;18:433-57. PMID 26431122
  25. Danielsen AV, Andreasen JJ, Dinesen B, et al.. Chronic post-thoracotomy pain after lung cancer surgery: a prospective study of preoperative risk factors. Scand J Pain. 2023;23:501-510. PMID 37327358
  26. Bengolea A, Chamorro F, Ramos JT, et al. Effectiveness and safety of the recombinant herpes zoster vaccine in different population groups: a systematic review and meta-analysis. Medicina (B Aires). 2024;84:959-970. PMID 39399936
  27. Lepot A, Elia N, Tramèr MR, et al. Preventing pain after breast surgery: A systematic review with meta-analyses and trial-sequential analyses. Eur J Pain. 2021;25:5-22. PMID 32816362
  28. Wang L, Guyatt GH, Kennedy SA, et al. Predictors of persistent pain after breast cancer surgery: a systematic review and meta-analysis of observational studies. CMAJ. 2016;188:E352-E361. PMID 27402075
  29. Wang L, Cohen JC, Devasenapathy N, et al. Prevalence and intensity of persistent post-surgical pain following breast cancer surgery: a systematic review and meta-analysis of observational studies. Br J Anaesth. 2020;125:346-357. PMID 32611524
  30. Jiwnani S, Ranganathan P, Patil V, et al. Pain after posterolateral versus nerve-sparing thoracotomy: A randomized trial. J Thorac Cardiovasc Surg. 2019;157:380-386. PMID 30195601
  31. Ding S, Wen S, Kang H, et al. Association of the incidence of postherpetic neuralgia with early treatment intervention of herpes zoster and patient baseline characteristics: A systematic review and meta-analysis of cohort studies. Int J Infect Dis. 2024;147:107181. PMID 39029866